Pharmacy Website
Clinic Website

Intelligence » Cystic Fibrosis » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation

Wednesday, December 12, 2018 -- by Kerstin Pohl, David P. Nichols, Jennifer L. Taylor-Cousar, Milene T. Saavedra, Matthew J. Strand, Jerry A. Nick, Preston E. Bratcher Cystic fibrosis (CF) is the most common life-shortening genetic disease and is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Several current therapies aim at improving availability and/or function of the mutant CFTR proteins. The combination therapeutic lumacaftor/ivacaftor (Orkambi, luma/iva) partially corrects folding and potentiates CFTR function impaired by the F508del mutation. Despite the potential for clinical benefit, a substantial number of patients discontinue treatment due to intolerable adverse effects. The aim of the present study is to identify differences between individuals who continued treatment and those who discontinued due to adverse respiratory effects